We speculate that hyperactive kinases, such as FLT3-ITD in AML cells or BCR-ABL in chronic myeloid leukemia cells and a subset of ALL cells [52], activate MYC and POLD1, and that this attenuates the cytotoxic effects of HDAC10 inhibition. Here, HDAC10 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.